Pulmonary arterial hypertension agent-1
Pulmonary arterial hypertension agent-1 is a phenylphosphate-prodrug of a prostacyclin with activation by lung phosphatases to release prostacyclin. Pulmonary arterial hypertension agent-1 can be used for the research of pulmonary arterial hypertension.
For research use only. We do not sell to patients.
- CAS No.: 1201082-00-9
- Formula: C26H41NO4
- Molecular Weight:431.61
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Pulmonary arterial hypertension agent-1 (Example 15) can release prostacyclin via pulmonary phosphatase activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1201082-00-9
-
Molecular Weight 431.61
-
Formula C26H41NO4
-
SMILES
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C/C(C2)=C\CCCC(OCCN(C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pulmonary arterial hypertension agent-1 Related Classifications
HY-148670 Related Classifications
Powered by Bioz